EUCTR2012-005048-46-IT进行中（未招募）不适用
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH - CENTRAL (ColorEctalavastiNTRiALdh)
Fondazione GISCAD0 个研究点开始时间: 2013年5月6日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Written informed consent
- •No prior treatment for advanced disease (adjuvant therapy allowed)
- •age < 75 years < 18 years
- •Histologically/cytologically confirmed advanced, colorectal cancer
- •At least one lesion measurable with CT or MRI scan
- •Performance Status (ECOG) 0-1 at study entry)
- •Life expectancy of at least 6 months
- •Neutrophils count =/> 1.5 x 109/L, platelets count =/> 100 x 109/L, HGB =/> 10 g/dL
- •total bilirubin < 1.5 x UNL • SGOT and SGPT =/< 2.5 x UNL (=/< 5 x UNL in patients with liver metastases)
- •Creatinine < 1.5 x UNL
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 75
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •. CNS metastases
- •Severe cardiovascular disease
- •Uncontrolled infections
- •Radiotherapy within 4 weeks of study entry
- •Any experimental drug administered within 4 weeks of study entry
- •Known hypersensitivity to study drug
- •Known drugs or alcohol abuse
- •Pregnant or lactating women (serum Betahcg test)
- •Other tumours, except in situ melanoma or cervix cancer if radically removed
- •Incapability to sign informed consent
研究者
相似试验
进行中（未招募）
不适用
Phase III study to compare two different chemotherapy treatments to determine whether the first line with the three drugs + bevacizumab followed by a second line with the same regimen may provide better results than treatment with two drugs + bevacizumab is the first and the second treatment lineEUCTR2014-004436-19-ITG.O.N.O.
已完成
2 期
Phase II trial of FOLFOXIRI + Bevacizumab in patients with untreated metastatic colorectal cancerPatients with metastatic colorectal cancerJPRN-UMIN000017102Translational Research Informatics Center, Foundation for Biomedical Research and Innovation45
进行中（未招募）
不适用
Bevacizumab+folfiri in untreated patients with advanced colorectal cancer. A phase II multicenter study of the Gruppo Oncologico dell'Italia Meridionale. (GOIM). - Bevacizumab+folfiri in untreated patients with advanced colorectal canceuntreated patients with advanced colorectal cancer.MedDRA version: 9.1Level: LLTClassification code 10010035Term: Colorectal cancer stage IVEUCTR2006-002887-25-ITGOIM GRUPPO ONCOLOGICO MERIDIONALE
已完成
2 期
Phase II trial of FOLFIRI plus Bevacizumab in second-line therapy after progression on bevacizumab with oxaliplatine-based chemotherapy in patients with metastatic colorectal cancer whose KRAS status are investigated.Recurrent or metastatic colorectal cancerJPRN-UMIN000004219Hyogo Cancer Center, Dept. of Gastrointestinal and Hepatobiliary Oncology40
已完成
2 期
Phase II study of FOLFIRI plus Bevacitumab in the treatment of Japanese patients with advanced colorectal cancer.Colorectal cancerJPRN-UMIN000001437Japan Clinical Cancer Research Organization40